The Scar Solution Natural Scar Removal

The Scar Solution Book

Get Instant Access

1. Bowen J. Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J Cutan Dis 1912;30:241-55.

2. Lee M, Wick M. Bowen's disease. Cancer J Clin 1990;40:237-42.

3. Frost C, Green A. Epidemiology of solar keratoses. Br J Dermatol 1994; 131:455-64.

4. Vitasa B, Taylor H, Strickland P et al. Association of non-melanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990;65:2811-17.

5. Schwartz R. The actinic keratosis. A perspective and update. Dermatol Surg 1997;23:1009-19.

6. Marks R, Jolley D, Dorevitch A et al The incidence of non-melanocytic skin cancers in an Australian population: results of a five-year prospective study. Med J Aus 1989;150:475-8.

7. Eedy D, Gavin G. Thirteen-year retrospective study of Bowen's disease in Northern Ireland. Br J Dermatol 1987;117:715-20.

8. Kossard S, Rosen R. Cutaneous Bowen's disease. J Am Acad Dermatol 1992;27:406-10.

9. Thestrup-Pederson K, Ravnborg L, Reymann F. Morbus Bowen. Acta Derm Venereol 1988;68:236-9.

10. Holman C, Armstrong B, Evans P et al. Relationship of solar keratoses and history of skin cancer to objective measures of actinic skin damage. Br J Dermatol 1984;110:129-38.

11. Green A, Beardmore G, Hart V et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988;19:1045-52.

12. Marks R, Staples M, Giles G. Trends in non-melanocytic skin cancer treated in Australia: the Second National Survey. Int J Cancer 1993;53:585-90.

13. Schwartz R. Therapeutic perspectives in actinic and other keratoses. Int J Dermatol 1996;35:533-8.

14. Preston D, Stern R. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.

15. Sanchez Yus E, de Diego V, Urrutia S. Large cell acanthoma: a cytologic variant of Bowen's disease. Am J Dermatopath 1988;10:197-208.

16. Reizner G, Chuang T, Elpern D, Stone J, Farmer E. Bowen's diseae (squamous cell carcinoma In situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol 1994;31:596-600.

17. Fiertz U. Catamnestic investigations of the side effects of therapy of skin diseases with inorganic arsenic. Dermatologica 1965;131:41-58.

18. Yeh S. Skin cancer in chronic arsenism. Hum Pathol 1967;4:469-85.

19. Yeh S, How S, Lin C. Arsenical cancer of the skin. Histologic study with special reference to Bowen's disease. Cancer 1968;21:312-39.

20. Shannon R, Strayer D. Arsenic-induced skin toxicity. Hum Toxicol 1989;8:99-104.

21. Cox N, Eedy D, Morton C. Guidelines for management of Bowen's disease. Br J Dermatol 1999;141:633-41.

22. Kettler A, Rutledge M, Tschen JG. Detection of human papillomavirus in nongenital Bowen's disease by in situ DNA hybridization. Arch Dermatol 1990; 126:777-81.

23. Collina G, Rossie E, Betelli S. Detection of human papillomavirus in extragenital Bowen's disease using in situ hybridization and polymerase chain reaction. Am J Dermatopath 1995;17:326-41.

24. Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology 1994;189:52.

25. Boddie AJ Jr, Fischer EP, Byers RM. Squamous carcinoma of the lower lip in patients under 40 years of age. South Med J 1977;70:711.

26. Glogau R. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:S23-S24.

27. Dodson J, DeSpain J, Hewett JE et al. Malignant potential of actinic keratoses and the controversy over treatments. A patient oriented perspective. Arch Dermatol 1991;127: 1029-31.

28. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000;115:273-7.

29. Jacobs D. Sebaceous carcinoma arising from Bowen's disease of the vulva. Arch Dermatol 1926;122:1191-3.

30. Saida T, Okabe Y, Uhara H. Bowen's disease with invasive carcinoma showing sweat gland differentiation. J Cutan Pathol 1989;16:222-6.

31. Kao G. Carcinoma arising in Bowen's disease. Arch Dermatol 1986;122:1124-6.

32. Beerman H. Tumors of the skin. Am J Med Sci 1946;211:480-504.

33. Graham J, Helwig E. Bowen's disease and its relationship to systemic cancer. Arch Dermatol 1959;80:133-159.

34. Epstein E. Association of Bowen's disease with visceral cancer. Arch Dermatol 1960;82:349-51.

35. Callen J, Headington J. Bowen's and non-Bowen's squamous intraepidermal neoplasia of the skin: relationship to internal malignancy. Arch Dermatol 1980;116:422-6.

36. Lycka B. Bowen's disease and internal malignancy. A meta-analysis. Int J Dermatol 1989;28:531-3.

37. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. British Association of Dermatologists. Br J Dermatol 1999; 141:633-41.

38. Stevens A, Raftery, J. Health Care Needs Assessment. In: Williams HC, ed. Dermatology. Oxford: Radcliffe Medical Press 1997:261-341.

39. Pierre P, Weil E, Chen S. Cryotherapy versus topical 5-fluorouracil therapy of actinic keratoses: a systematic review. Allergologie 2001;24:204-5.

40. Lubritz R, Smolewski S. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982;7:631-2.

41. Dinehart S. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:S25-S28.

42. Ahmed I, Berth-Jones J, Charles-Holmes S, Callaghan C, Ilchyshyn A. Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study. Br J Dermatol 2000; 143:759-66.

43. Cox N, Dyson P. Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen's disease and other malignant skin lesions. Br J Dermatol 1995;133:60-5.

44. Drnovsek-Olup B, Vedlin B. Use of Er:YAG laser for benign skin disorders. Lasers Surg Med 1997;21:13-19.

45. Jiang SB, Levine VJ, Nehal KS, Baldassano M, Kamino H, Ashinoff RA. Er:YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000;26:437-40.

46. Gordon K, Garden J, Robinson J. Bowen's disease of the distal digit. Dermatol Surg 1996;22:723-8.

47. Tantikun N. Treatment of Bowen's disease of the digit with carbon dioxide laser. J Am Acad Dermatol 2000;43: 1080-3.

48. Barta U, Grafe T, Wollina U. Radiation therapy for extensive actinic keratosis. J Eur Acad Dermatol Venereol 1999;14:293-5.

49. Stevens D, Kopf A, Gladstein A, Bart R. Treatment of Bowen's disease with grenz rays. Int J Dermatol 1977; 16: 329-39.

50. Caccialanza M, Piccinno R, Beretta M, Sopelana N. Radiotherapy of Bowen's disease. Skin Cancer 1993;8:115-18.

51. Umebayashi Y, Uyeno K, Tsujii H, Otsuka F. Proton radiotherapy of skin carcinoma. Br J Dermatol 1994;130: 88-91.

52. Chung Y, Lee J, Bang D, Lee J, Kyung B, Lee M. Treatment of Bowen's disease with a specially designed radioactive skin patch. Eur J Nucl Med 2000: 27:842-6.

53. Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol 1996;133: 638-44.

54. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Ponciano DC, Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid v 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995;131:176-81.

55. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freeman RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid v 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997;23:191-6.

56. Spira M, Frreman R, Arfai P, Gerow F, Hardy S. A comparison of chemical peeling, dermabrasion, and 5-fluorouracil in cancer prophylaxis. J Surg Oncol 1971;3:367-8.

57. Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol 1986;14:661-8.

58. Sturm H. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol 1979;1:513-22.

59. Hiruma M, Kawada A. Hyperthermic treatment of Bowen's disease with disposable chemical pocket warmers: a report of 8 cases. J Am Acad Dermatol 2000;43:1070-5.

60. Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki B, Jablonska S. Topical treatment of mulitple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: A doubleblind, comparative study. J Am Acad Dermatol 1991;24:448-51.

61. Alirezai M, Dupuy P, Amblard P et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994;30:447-51.

62. Kulp-Shorten CL, Konnikov N, Callen JP. Comparative evaluation of the efficacy and safety of masoprocol and 5-fluorouracil cream for the treatment of multiple actinic keratoses of the head and neck. J Geriatr Dermatol 1993;1:161-8.

63. Breza T, Taylor R, Eaglstein W. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol 1976;112:1256-8.

64. Carter V, Smith K, Noojin R. Xeroderma pigmentosum. Treatment with topically applied fluorouracil. Arch Dermatol 1968;98:526-7.

65. Simmonds W. Topical management of actinic keratoses with 5-fluorouracil: results of a 6-year follow-up study. Cutis 1972;10:737-41.

66. Neldner K. Prevention of skin cancer with topical 5-Fluorouracil. Rocky Mountain Med J 1966;Nov:74-8.

67. Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol 1977;113:906-8.

68. Marrero G, Katz B. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol Surg 1998;24:973-8.

69. Klein E, Stoll H, Milgrom H, Helm F, Walker M. Tumors of the Skin. XII. Topical 5-fluorouracil for epidermal neoplasms. J Surg Oncol 1971;3:331-49.

70. Schultz E, Falkson G. Benign and malignant skin diseases response to topical 5-fluorouracil. Med Proc 1970;Feb: 41-6.

71. Dogliotti M. Actinic keratoses in Bantu Albinos: Clinical experiences with the topical use of 5-fluorouracil. S Afr Med J 1973;47:2169-72.

72. Dillaha C, Jansen G, Honeycutt W, Holt G. Further studies with topical 5-fluorouracil. Arch Dermatol 1965;92:410-13.

73. Ott F, Eichenberger-De Beer H, Storck H. The local treatment of precancerous skin conmdition with 5-Fluorouracil ointment. Dermatologica 1970;140:109-13.

74. Robinson T, Kligman A. Treatment of solar keratoses of the extremities with retinoic acid and 5-Fluorouracil. Br J Dermatol 1975;92:703-6.

75. Bercovitch L. Topical chemotherapy of actinic keratoses of upper extremities with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol 1987; 116: 549-52.

76. Goncalves J. Treatment of solar keratoses with a 5-fluorouracil and salicylic acid varnish. Br J Dermatol 1975;92:85-8.

77. Dillaha C, Jansen G, Honeycutt WM et al. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1963;88:247-56.

78. Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatol Treat 1989;1:65-8.

79. Welch M, Grabski W, McCollough M, Skelton H, Smith K, Menon P. 5-fluorouracil iontophoretic therapy for Bowen's disease. J Am Acad Dermatol 1997;36:956-8.

80. Bell H, Rhodes L. Bowen's disease-a retrospective review of clinical management. Clin Exp Dermatol 1999;24: 336-9.

81. Stone N, Burge S. Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream. Br J Dermatol 1999;140:963-91.

82. Dillaha C, Jansen G, Honeycutt W. Topical therapy with fluorouracil. Prog Dermatol 1966;1:1-2.

83. Jansen G, Dillaha C, Honeycutt W. Bowenoid conditions of the skin: treatment with topical 5-fluorouracil. Southern Med J 1967;60:185-8.

84. Unis M. Short-term intensive 5-fluorouracil treatment of actinic keratoses [see comments]. Dermatol Surg 1995;21:162-3.

85. Pearlman D. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991;25:665-7.

86. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998;38:77-80.

87. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001;144:1050-3.

88. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens M. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44: 462-70.

89. Smith K, Germain M, Sketon H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg 2001;27: 143-6.

90. Jeffes EW, McCullough JL, Weinstein GD et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study. Arch Dermatol 1997;133:727-32.

91. Ormrod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol 2000; 1: 133-9.

92. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999;41: 414-18.

93. Morton C, Whitehurst C, Moore J, Mackie R. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000; 143: 767-72.

94. Morton C, Whitehurst C, Moseley H, McColl J, Moore J, Mackie R. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135:766-71.

95. Jones C, Mang T, Cooper M, Wilson B, Stoll H. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol 1992;27:979-82.

96. Svanberg K, Anderson T, Killander D, Wang I, Sternam U, Andersson-Engels S. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical alpha-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51.

97. Wong T, Sheu H, Lee Y, Fletcher R. Photodynamic therapy for Bowen's disease (squamous cell carcinoma in situ) of the digit. Dermatol Surg 2001;27:452-5.

98. Stables G, Stringer M, Robinson D, Ash D. Large patches of Bowen's disease treated by topical aminolevulinic acid photodynamic therapy. Br J Dermatol 1997;136:957-60.

99. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferoxamine. Br J Dermatol 1995;133:282-8.

100. Olsen EA, Abernethy ML, Kulp-Shorten C et al. A doubleblind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991;24(5 Pt 1):738-43.

101. Epstein E. Warning! Masoprocol is a potent sensitizer. J Am Acad Dermatol 1994;31 (2 Pt 1):295-7.

102. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997;38:187-9.

103. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2-5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997;133:1239-42.

104. Burgess GH, Bloch A, Stoll H, Milgrom H, Helm F, Klein E. Effect of topical tubercidin on basal cell carcinomas and actinic keratoses. Cancer 1974;34:250-3.

105. Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett 1991;59:183-92.

106. Moriarty M, Dunn J, Darragh A, Lambe R, Brick I. Etretinate in treatment of actinic keratosis. Lancet 1982;i(8268):364-5.

107. Watson AB. Preventative effect of etretinate therapy on multiple actinic keratoses. Cancer Detect Prev 1986;9:161-5.

108. Thianprasit M. Chronic cutaneous arsenism treated with aromatic retinoid. J Med Assoc Thailand 1984;67: 93-100.

109. Edwards L, Levine N, Weidner M, Piepkorn M, Smiles K. Effect of intralesional a2-interferon on actinic keratoses. Arch Dermatol 1986;122:779-82.

110. Edwards L, Levine N, Smiles K. The effect of topical interferon Alpha2b on actinic keratoses. J Dermatol Surg Oncol 1990;16:446-9.

111. Dyall-Smith D. Intralesional bleomycin. Australas J Dermatol 1998;39:123-4.

112. Weinstock MA, Bingham SF, Cole GW et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol 2001;137:1055-8.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment